Abstract
Diabetic foot infections (DFI) are the major cause of non-traumatic amputations of lower extremities. Important predisposing factors for the development of DFI are peripheral neuropathy and diabetic angiopathy. The most common pathogen isolated in early DFI is Staphylococcus aureus. Chronic long-lasting lesions accompanied by severe ischemia of lower extremities usually have polymicrobial etiology. In patients with long-term antimicrobial therapy there is a high probability of multiresistant pathogens. The main purpose of the treatment of DFI is to save the foot and its functions. Antimicrobial therapy, in parallel with surgical procedures, is an important method of treatment of DFI. The choice of antimicrobials should be based on microbiological results, local data on antimicrobial resistance and clinical response on empirically administered therapy. Duration of antimicrobial therapy depends on the severity of infection, adequacy of surgical procedures, and the degree of vascular insufficiency. Surgical treatment is essential in the presence of deep abscess, phlegmon, bones/joints destruction, and severe ischemia.
-
1.
Lipsky B., Berendt A., Deery H.G. et al. Diagnosis and treatment of diabetic foot infections. CID 2004; 39:885-910.
-
2.
Jeffcoate W, Harding K. Diabetic foot ulcers. Lancet 2003; 361:1545-51.
-
3.
Joshi N, Caputo G, Weitekamp M, Karchmer A. Infections in patients with diabetes mellitus. N Engl J Med 1999; 341:1906-12.
-
4.
Lipsky B, Pecoraro R, Wheat L. The diabetic foot: soft tissue and bone infection. Infect Dis Clin North Am 1990; 4:409-32.
-
5.
Дедов И.И., Галстян Г.Р., Токмакова А.Ю., Удовиченко О.В., Синдром диабетической стопы. Пособие для врачей; Москва, 2003: 9-11.
-
6.
Urbanic-Rovan V., Gubina M. Bacteria in superficial diabetic foot ulcers. Diabet Med 2000; 17:814-5
-
7.
Gerding DN. Foot infections in diabetic patients: the role of anaerobes. Clin Infect Dis 1995; 20 (suppl 2):S283-8.
-
8.
Hartemann-Heurtier A., Robert J., Jacqueminet S., et al. Diabetic foot ulcer and multidrug-resistant organisms: risk factors and impact. Diabet Med 2004; 21:710-5
-
9.
Eady EA, Cove JH. Staphylococcal resistance revisited: community-acquired methicillin-resistant Staphylococ cus aureus – an emerding problem for the management of skin and soft tissue infections. Curr Opin Infect Dis 2003; 16:103-24.
-
10.
Dang C, Prasad Y, Bouton A, Jude EB. Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem. Diabet Med 2003; 20:159-61.
-
11.
Centers for Disease Control and Prevention. Vancomycin-resistant Staphylococcus aureus – Pennsylvania, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:902.
-
12.
Bessman AN, Geirger PJ, Canawati H. Prevalence of Corynebacteria in diabetic foot infections. Diabetes Care 1992; 15:1531-3.
-
13.
Ge Y., MacDonald D., Hait H., Lipsky B., Zasloff M., Holroyd K. Microbiological profile of infected diabetic foot ulcers. Diabet Med 2002; 19:1032-4.
-
14.
Bowler PG, Duerden B.I., Armstrong D.G. Wound microbiology and associated approaches to wound management. Clin Microbiol Rev 2001; 14:244-69.
-
15.
International Working Group on the Diabetic Foot. International consensus on the diabetic foot. Brussels: International Diabetes Foundation, May 2003.
-
16.
Calhoum J.H., Cantrell J., Cobos J., et al. Treatment of diabetic foot infections: Wagner classification, therapy, and outcome. Foot Ankle 1988; 9:101-6.
-
17.
Levin M.E. Classification of diabetic foot wound. Diabetes Care 1998; 21:681.
-
18.
O, Meara S.M., Cullum N.A., Majid M., Sheldon T.A., Systematic review of antimicrobial agents used for chronic wounds. Br J Surg 2001; 88:4-21.
-
19.
Edmonds M., Foster A., The use of antibiotics in the diabetic foot. Am J Surg 2004; 187:25S-28S.
-
20.
Chantelau E., Tanudjaja T., Altenhofer F., Ersanli Z., La ci gova S., Metzger C. Antibiotic treatment for un com plicated neuropatic forefoot ulcers in diabetes: a controlled trial. Diabet Med 1996;13:156-9.
-
21.
Hirschl M., Hirschl A.M. Bacterial flora in mal perforant and antimicrobial treatment with ceftriaxone. Chemotherapy 1992; 38: 275-80.
-
22.
Lipsky B.A. A current approach to diabetic foot infections. Curr Infect Dis Rep 1999; 1:253-60.
-
23.
Lipsky B.A., MacDonald D., Litska P. Treatment of infected diabetic foot ulcers: topical MSI-78 vs. oral ofloxacin. Diabetologia 1997; 40: 482.
-
24.
Tan J.S., Friedman N. M., Hazelton-Miller C, Flanagan J.P, File T.M. Can aggressive treatment of diabetic foot infections reduce the need for above-ankle amputation? Clin Infect Dis 1996; 15: 1257-60.
-
25.
Pinzur M.S., Pinto M.A., Schon L.C., Smith D.G. Controversies in amputation surgery. Instr Course Lect 2003; 52:445-51.
-
26.
Chang B.B., Darling R.C., Paty P.S., Lloyd W.E., Shah D.M., Leather R.P. Expeditious management of ischemic invasive foot infections. Cardiovasc Surg 1996; 4:792-5.
-
27.
Gough A., Clapperton M., Ronaldo N., Foster A.V., Phil pott-Howard J., Ed monds M.E., Randomized placebo-controlled trial of gra nu locyte colony-stimulating factor in diabetic foot infection. Lancet 1997; 350:855-9.
-
28.
De Lalla F., Pelizzer G., Strazzabosco M., et al. Randomized prospective controlled trial of recombinant granulocyte colony-stimulating factor as adjunctive therapy for limb-threatening diabetic foot infection. Antimicrob Agents Chemother 2001; 45:1094-8.
-
29.
Lipsky B.A., Berendt A.R., Embil J., De Lalla F. Diagnosing and treating diabetic foot infections. Diabetes Metab Res Rev 2004; 20 (suppl 1):S 56-64.
-
30.
Kranke P., Bennett M., Roeckl-Wiedmann I., Debus S. Hyper baric oxygen therapy for chronic wounds. Cochrane Database Syst Rev 2004:CD004123.
-
31.
Bonham P. A critical review of literature: diagnosing and treatment of osteomyelitis in patients with diabetes and foot ulcers. J Wound Ostomy Continence Nurs 2001; 28:141-61.
-
32.
Khatri G., Wagner D.K., Sohnle P.G. Effect of bone biopsy in guiding antimicrobial therapy for osteomyelitis complicating open wounds. Am J Med Sci 2001; 321:367-71
-
33.
Jeffcoate W.J., Lipsky B.A., Controversies in diagnosing and managing osteomyelitis of the foot in diabetes. Clin Infect Dis 2004; 39 (suppl 2):115-22.
-
34.
Senneville E., Yazdznpanah Y., Cazaubiel M., et al Rifampicin-ofloxacin oral regiment for the treatment of mild to moderate diabetic foot osteomyelitis. J Antimicrob Chemother 2001; 48:927-30.
-
35.
Grayson M.L., Gibbons G.W., Habershaw G.M., et al. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients Clin Infect Dis 1994; 18:683-93.
-
36.
Eneroth M., Larsson J., Apelqvist J. Deep foot infections in patients with diabetes and foot ulcers: an entity with different characteristics, treatments, and prognosis. J Diabetes Complications 1999; 13;254-63
-
37.
Perncevich E.N., Kaye K.S., Strausbaugh L.J. Fis - man D.N., Harris A.D. Acceptable rates of treatment failure in osteomyelitis involving the diabetic foot: a survey of infectious diseases specialists Infectious Diseases Society of America Emerging Infections net work. Clin Infect Dis 2004; 38:976-82.